RNA Therapeutics Part B
- 1st Edition, Volume 204 - March 6, 2024
- Imprint: Academic Press
- Editors: Dinh-Toi Chu, Van Thai Than
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 4 4 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 4 5 - 0
RNA Therapeutics, Part B, Volume 204 updates on a new class of medication based on RNA molecules, with chapters on a variety of topics, including RNA therapeutics for cardio… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteRNA Therapeutics, Part B, Volume 204 updates on a new class of medication based on RNA molecules, with chapters on a variety of topics, including RNA therapeutics for cardiovascular disorders, RNA therapeutics for kidney injury, RNA therapeutics for beta-thalassemia, RNA therapeutics for infectious diseases, RNA therapeutics for reproductive diseases, Potential of RNA and transcriptomic data to drive drug repurposing for various diseases, RNA therapeutics for glioma/glioblastoma, RNA therapeutics for regenerative medicine, Advances in the liposome-based delivery systems for RNA therapeutics in cancer, Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics in cancer, and more.
- Covers RNA therapeutics' history and future perspectives
- Discusses the processes of RNA therapeutical development
- Presents recent applications of RNA therapeutic in clinics
- Provides the advantages and disadvantages of RNA therapeutics
Lectures, learders and experts on molecular bioledicnes, and students in Biotechnology, Clinicians and Healthcare Professionals, Pharmaceutical, and anyone who are particularly interested in RNA therapeutics
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Acknowledgements
- Chapter One: RNA interference-based therapies for atherosclerosis: Recent advances and future prospects
- Abstract
- 1 Introduction
- 2 The mechanism of siRNAs action
- 3 lncRNA inhibition for the treatment of cardiovascular diseases
- 4 MiRNA biogenesis and target recognition
- 5 The diverse role of miRNAs in different cells in atherosclerosis
- 6 The prospect of MiRNAs as diagnostic biomarkers in atherosclerosis
- 7 MiRNAs–based therapies approach for atherosclerosis
- 8 Potential future research directions
- References
- Chapter Two: An update on the therapeutic role of RNAi in NAFLD/NASH
- Abstract
- 1 Introduction
- 2 Nonalcoholic fatty liver disease: prevalence, clinical management, and risk factors
- 3 Nonalcoholic steatohepatitis: prevalence, clinical management, and risk factors
- 4 RNA interference: mechanisms of action, design, delivery, and applications
- 5 Therapeutic role of RNAi in NAFLD
- 6 Therapeutic role of RNAi in NASH
- 7 Future perspective and limitations
- 8 Conclusion
- References
- Chapter Three: RNA therapeutics for kidney injury
- Abstract
- 1 Introduction
- 2 Types of RNA-therapy involved in kidney injury
- 3 siRNAs
- 4 Different kidney cells affected by RNA-based therapeutics
- 5 Mesangial cells
- 6 Proximal tubular cells
- 7 RNA-loaded vehicles ligands for RNA therapy in kidney
- 8 Antibodies
- 9 Peptide sequences
- 10 Small molecules
- 11 Carbohydrate derivatives
- 12 Nanotechnology and renal RNA therapy
- 13 Future prospectives
- Acknowledgment
- References
- Chapter Four: RNA therapeutics for β-thalassemia
- Abstract
- 1 Introduction
- 2 Classification of RNA therapeutics
- 3 Aptamer
- 4 RNA therapy for treatment of beta-thalassemia
- 5 Conclusion and future perfectives
- References
- Chapter Five: RNA therapeutics for infectious diseases
- Abstract
- 1 Introduction
- 2 RNA vaccine for infectious disease
- 3 RNA-therapeutic application in infectious diseases
- References
- Chapter Six: Application of RNA-based therapeutics in glioma: A review
- Abstract
- Abbreviations
- 1 Introduction
- 2 The platforms of RNA-based therapeutics in GBM
- 3 Conclusion
- References
- Chapter Seven: RNA therapeutics for regenerative medicine
- Abstract
- 1 Introduction
- 2 The development of RNA therapeutics for regenerative medicine
- 3 Type of RNA therapeutics for regenerative medicine
- 4 The mechanisms of RNA therapeutics for regenerative medicine
- 5 Conclusion
- References
- Chapter Eight: Advances in liposome-based delivery of RNA therapeutics for cancer treatment
- Abstract
- 1 Introduction
- 2 Liposomes: Efficient drug delivery platforms
- 3 Engineered liposomes as nanocarriers for RNA-based cancer therapeutics
- 4 Conclusion
- References
- Chapter Nine: Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics
- Abstract
- 1 Introduction
- 2 Polymeric nanoparticle drug delivery
- 3 siRNA delivery systems
- 4 Evaluation of multiple RNA cargos in nanoparticle-based systems
- 5 Analyzing the structure of RNA-loaded lipidoid-polymer nanoparticles
- 6 Lipid nanoparticle vaccine storage optimization
- 7 Optimized core polymer enhances siRNA effects
- 8 Conclusion
- Acknowledgments
- References
- Chapter Ten: Advances in RNA therapeutics for modulation of ‘undruggable’ targets
- Abstract
- 1 Introduction
- 2 The undruggable genome
- 3 Future directions
- References
- Chapter Eleven: RNA therapeutics for diarrhea
- Abstract
- 1 Introduction
- 2 The development of RNA therapeutics for diarrhea
- 3 Type of RNA therapeutics for diarrhea
- 4 The mechanisms of RNA therapeutics for diarrhea
- 5 Conclusion
- References
- Chapter Twelve: Biosafety and regulatory issues of RNA therapeutics
- Abstract
- Abbreviations
- 1 Introduction
- 2 Risks of RNA therapeutics
- 3 Biosafety of RNA therapeutics
- 4 Regulatory of RNA therapeutics
- 5 Conclusion
- References
- Index
- Edition: 1
- Volume: 204
- Published: March 6, 2024
- No. of pages (Hardback): 358
- No. of pages (eBook): 300
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443235443
- eBook ISBN: 9780443235450
DC
Dinh-Toi Chu
Dr. Chu is currently the Director of the Center for Biomedicine and Community Health and the Dean of the Faculty of Applied Sciences, International School, Vietnam National University (VNU), Hanoi, Vietnam. He is also a visiting Professor at the Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan. He achieved a Doctor of Veterinary Medicine degree from Vietnam in 2006, a Master of Biological Science from in South Korea in 2011. From 2011 to 2015, he participated in an EU-funded program in. Poland for the Ph.D. program in diet-induced obesity, genetic effects, and epigenetic regulations of lipid metabolism and obesity, and got a PhD in medicine (medical Biology). Dr. Chu continued his journey as a postdoc and researcher in molecumar biomoedicine under a Marie Curie Postdoctoral Research Fellowship at the Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo (Norway) from 2015 to 2018. Up to now, he has over 190 WoS/Scopus publications in biomedicne and community health with more than 21000 citations (Scopus, updated by 5/2023). He has also reviewed over 40 qualified scientific journals with more than 300 manuscripts and handed over 250 manuscripts as an editor for several WoS/Scopus journals such as Bioengineered and PLOS ONE. In 2022, the Stanford List recognized him as the Top 2% Scientists in the World.
Affiliations and expertise
Director, Center for Biomedicine and Community Health, Dean, Faculty of Applied Sciences International School, Vietnam National University, Hanoi 144 Xuan Thuy, Cau Giay, Hanoi, VietnamVT
Van Thai Than
Dr. Thai received his DVM in 2006 in Vietnam; a PhD in biomedicine in 2014 at the Faculty of Medicine, Chung-Ang University, Korea. He served as Postdoctoral Researcher and Research Professor at the Faculty of Medicine, Chung-Ang University for three consecutive years before joining the Faculty of Biotechnology, Nguyen Tat Thanh University, then Faculty of Biotechnology, Chemistry, and Environmental Engineering, Phenikaa University; and now Faculty of Applied Sciences, International School, VNU. His interest fields are included microbial epidemiology, microbial evolution, microbial immunology, gene expression, vaccine, and sub-unit vaccine. Dr. Thai has extensive working experiences with various types of microbes, including the human microbes (Rotavirus, Norovirus, Parechovirus), the animal microbes (Influenza Virus, Foot-and-Mouth Disease Virus, Infectious Bronchitis Virus), and plant microbes (Sri-Lanka Cassava Mosaic Virus, Enterobacter cloacae). His most recent research is the infection of Human Papilloma Virus (HPV) in Vietnam. This research focuses on HPV detection, HPV genotype identification, HPV vaccine evaluation. The results will provide evidence for that the HPVs remain as a reservoir of causing human papillomavirus carcinogen as well as suggesting for the development of appropriate HPV detection kit and vaccine in Vietnam.
Affiliations and expertise
Center for Biomedicine and Community Health, Faculty of Applied Sciences International School, Vietnam National University, Hanoi 144 Xuan Thuy, Cau Giay, Hanoi, VietnamRead RNA Therapeutics Part B on ScienceDirect